EGFR and central nervous system cancer: In tumors from the X+4 regime there was an increase in phospho-EGFR, although no significant changes were observed in the amount of phospho-NFkB (Figure 4A), a MES driver in gliomas.31 The changes observed in the X+13 responsive tumors were paralleled by an increase in the expression of several PN markers (Figure 4B) and the downregulation of the transcription of MES genes (Figure 4C), compared to control tumors.